Skye Bioscience announcea the appointment of Dr. Annalisa Jenkins, MBBS, FRCP, to the Company’s Board of Directors. Dr. Jenkins currently provides board level and consulting services to organizations across the life science and healthcare industry. She previously served as President and CEO of Plaquetec Therapeutics and of Dimension Therapeutics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SKYE:
- Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
- Skye Bioscience completes enrollment of Phase 2a trial of SBI-100
- Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
- Skye Bioscience Nears Nasdaq Listing with Updated Finances
- Fly Insider: Skye Bioscience, Coinbase among week’s notable insider trades
